Status:
COMPLETED
Safety and Efficacy of MBI 226 2.5% and 5.0% Topical Acne Solutions in the Treatment of Acne
Lead Sponsor:
BioWest Therapeutics Inc
Conditions:
Acne Vulgaris
Acne
Eligibility:
All Genders
13+ years
Phase:
PHASE2
Brief Summary
This study investigates the safety and efficacy of MBI 226 2.5% and 5.0% Acne Solutions, applied topically for six weeks, in the treatment of acne.
Eligibility Criteria
Inclusion
- Males and females, ages 13 and up, exhibiting high levels of facial P. acnes
- Presence of inflammatory and non-inflammatory lesions
Exclusion
- Acne conglobata, acne fulminans, or secondary acne (chlorine, drug-induced acne, etc.)
- Active facial cysts
Key Trial Info
Start Date :
October 1 2000
Trial Type :
INTERVENTIONAL
End Date :
September 1 2001
Estimated Enrollment :
75 Patients enrolled
Trial Details
Trial ID
NCT00211523
Start Date
October 1 2000
End Date
September 1 2001
Last Update
September 21 2005
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.